Basal cell carcinoma (BCC) is extremely common, and its incidence continues to rise.
Objective:
This review presents the literature pertaining to the epidemiology, pathogenesis, and risk factors associated with BCC.
Conclusions:
The risk of developing BCC depends on both genetic predisposition and exposure to risk. Fair-skinned people account for the overwhelming majority of patients, beyond what would be expected by skin phototype alone. Damage to multiple lines of defense appears to be necessary for cancer development and spread. This damage distorts the concerted effort of deoxyribonucleic acid (DNA) repair, immunosurveillance, and cellular growth regulation to protect against malignant progression. Ultraviolet light exposure is the most critical modifiable factor determining early expression and frequency of BCC development.
Get full access to this article
View all access options for this article.
References
1.
SilvermanMKKopfAWBartRS. Recurrence rates of treated basal cell carcinomas. Part 1: Overview. J Dermatol Surg Oncol1991;17:713–8.
2.
AlbertMRWeinstockMA. Keratinocyte carcinoma. CA Cancer J Clin2003;53:292–302.
3.
GilbodyJSAitkenJGreenA. What causes basal cell carcinoma to be the commonest cancer?Aust J Public Health1994;18:218–21.
4.
GallagherRPMaBMcLeanDI. Trends in basal cell carcinoma, squamous cell carcinoma, and melanoma of the skin from 1973 through 1987. J Am Acad Dermatol1990;23(3 Pt 1): 413–21.
5.
MillerDLWeinstockMA. Nonmelanoma skin cancer in the United States: Incidence. J Am Acad Dermatol1994;30(5 Pt 1): 774–8.
6.
DemersAANugentZMihalcioiuC. Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population. J Am Acad Dermatol2005;53:320–8.
7.
American Cancer Society.Cancer facts and figures. Atlanta (GA): American Cancer Society; 2005.
8.
Canadian Cancer Society.Canadian cancer statistics. Toronto: Canadian Cancer Society; 2005.
9.
HousmanTSFeldmanSRWillifordPM. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol2003;48:425–9.
10.
FearsTRScottoJ. Changes in skin cancer morbidity between 1971–72 and 1977–78. J Natl Cancer Inst1982;69:365–70.
11.
KaragasMRGreenbergERSpencerSK. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer1999;81:555–9.
12.
WroneDASwetterSMEgbertBM. Increased proportion of aggressive-growth basal cell carcinoma in the Veterans Affairs population of Palo Alto, California. J Am Acad Dermatol1996;35:907–10.
13.
ChristensonLJBorrowmanTAVachonCM. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA2005;294:681–90.
14.
HarrisRBGriffithKMoonTE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985–1996. J Am Acad Dermatol2001;45:528–36.
15.
HoyWE. Nonmelanoma skin carcinoma in Albuquerque, New Mexico: Experience of a major health care provider. Cancer1996;77:2489–95.
16.
BeckensteinMSWindleBH. Basal cell carcinoma in black patients: The need to include it in the differential diagnosis. Ann Plast Surg1995;35:546–8.
17.
LesherJLJrd'AubermontPCBrownVM. Morpheaform basal cell carcinoma in a young black woman. J Dermatol Surg Oncol1988;14:200–3.
18.
HalderRMBridgeman-ShahS. Skin cancer in African Americans. Cancer1995;75(2 Suppl):667–73.
19.
FearsTRScottoJ. Estimating increases in skin cancer morbidity due to increases in ultraviolet radiation exposure. Cancer Invest1983;1:119–26.
20.
TingPTKasperRArletteJP. Metastatic basal cell carcinoma: Report of two cases and literature review. J Cutan Med Surg2005;9:10–15.
21.
FarmerERHelwigEB. Metastatic basal cell carcinoma: A clinicopathologic study of seventeen cases. Cancer1980;46:748–57.
22.
WeinstockMA. Epidemiologic investigation of nonmelanoma skin cancer mortality: The Rhode Island Follow-Back Study. J Invest Dermatol1994;102:6S–9S.
23.
HahnWCWeinbergRA. Rules for making human tumor cells. N Engl J Med2002;347:1593–603.
24.
ya-GrosjeanLCouve-PrivatS. Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett2005;225:181–92.
25.
LacourJP. Carcinogenesis of basal cell carcinomas: Genetics and molecular mechanisms. Br J Dermatol2002;146Suppl 61:17–9.
26.
YamazakiFAraganeYKawadaATezukaT. Immunohistochemical detection for nuclear beta-catenin in sporadic basal cell carcinoma. Br J Dermatol2001;145:771–7.
27.
El-BahrawyMEl-MasryNAlisonM. Expression of beta-catenin in basal cell carcinoma. Br J Dermatol2003;148:964–70.
28.
SaldanhaGGhuraVPotterLFletcherA. Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation. Br J Dermatol2004;151:157–64.
29.
KimonisVEGoldsteinAMPastakiaB. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet1997;69:299–308.
30.
GailaniMRStahle-BackdahlMLeffellDJ. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet1996;14:78–81.
31.
TabsSAvciO. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol2004;14:96–102.
32.
AtharMLiCTangX. Inhibition of Smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res2004;64:7545–52.
33.
RadyPScinicarielloFWagnerRFJrTyringSK. p53 mutations in basal cell carcinomas. Cancer Res1992;52:3804–6.
34.
DickerTSillerGSaundersN. Molecular and cellular biology of basal cell carcinoma. Australas J Dermatol2002;43:241–6.
35.
OuhtitANakazawaHArmstrongBK. UV-radiation-specific p53 mutation frequency in normal skin as a predictor of risk of basal cell carcinoma. J Natl Cancer Inst1998;90:523–31.
36.
Kore-edaSHoriguchiYUedaM. Basal cell carcinoma cells resemble follicular matrix cells rather than follicular bulge cells: Immunohistochemical and ultrastructural comparative studies. Am J Dermatopathol1998;20:362–9.
37.
TaylorGLehrerMSJensenPJ. Involvement of follicular stem cells in forming not only the follicle but also the epidermis. Cell2000;102:451–61.
38.
KumakiriMHashimotoK. Ultrastructural resemblance of basal cell epithelioma to primary epithelial germ. J Cutan Pathol1978;5:53–67.
39.
LearJTHobanPStrangeRCFryerAA. Basal cell carcinoma: From host response and polymorphic variants to tumour suppressor genes. Clin Exp Dermatol2005;30:49–55.
40.
SauderDN. Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions. J Cutan Med Surg2004;8Suppl 3:3–12.
41.
MorrisonH. Photochemistry and photobiology of urocanic acid. Photodermatology1985;2:158–5.
42.
NorvalMGibbsNKGilmourJ. The role of urocanic acid in UV-induced immunosuppression: Recent advances (1992–1994). Photochem Photobiol1995;62:209–17.
43.
PentlandAPSchogginsJWScottGA. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis1999;20:1939–44.
44.
FischerSMLoHHGordonGB. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog1999;25:231–40.
45.
RamdialPKMadareeAReddyRChettyR. bcl-2 protein expression in aggressive and non-aggressive basal cell carcinomas. J Cutan Pathol2000;27:283–91.
46.
BoldriniLLogginiBGisfrediS. Mutations of Fas (APO-1/CD95) and p53 genes in nonmelanoma skin cancer. J Cutan Med Surg2003;7:112–8.
47.
BoldriniLLogginiBGisfrediS. Evaluation of telomerase in non-melanoma skin cancer. Int J Mol Med2003;11:607–11.
48.
HerouyY. Matrix metalloproteinases in skin pathology (review). Int J Mol Med2001;7:3–12.
49.
MonhianNJewettBSBakerSRVaraniJ. Matrix metalloproteinase expression in normal skin associated with basal cell carcinoma and in distal skin from the same patients. Arch Facial Plast Surg2005;7:238–43.
50.
WallingHWFoskoSWGeraminejadPA. Aggressive basal cell carcinoma: Presentation, pathogenesis, and management. Cancer Metastasis Rev2004;23:389–402.
51.
MaiolinoPDeVGRestucciB. Expression of vascular endothelial growth factor in basal cell tumours and in squamous cell carcinomas of canine skin. J Comp Pathol2000;123:141–5.
52.
Van ScottEJReinertsonRP. The modulating influence of stromal environment on epithelial cells studied in human autotransplants. J Invest Dermatol1961;36:109–31.
53.
HalesSAStampGEvansMFlemingKA. Identification of the origin of cells in human basal cell carcinoma xenografts in mice using in situ hybridization. Br J Dermatol1989;120:351–7.
54.
BryskMMSantschiCHBellT. Culture of basal cell carcinoma. J Invest Dermatol1992;98:45–9.
55.
KelfkensGde GruijlFRvan der LeunJC. Ozone depletion and increase in annual carcinogenic ultraviolet dose. Photochem Photobiol1990;52:819–23.
56.
OikarinenARaitioA. Melanoma and other skin cancers in circumpolar areas. Int J Circumpolar Health2000;59:52–6.
57.
de LaatJMde GruijlFR. The role of UVA in the aetiology of non-melanoma skin cancer. Cancer Surv1996;26:173–91.
58.
AlmahroosMKurbanAK. Ultraviolet carcinogenesis in nonmelanoma skin cancer. Part I: Incidence rates in relation to geographic locations and in migrant populations. Skinmed2004;3:29–35.
CoronaRDogliottiED'ErricoM. Risk factors for basal cell carcinoma in a Mediterranean population: Role of recreational sun exposure early in life. Arch Dermatol2001;137:1162–8.
61.
NaldiLDiLandroAD'AvanzoBParazziniF. Host-related and environmental risk factors for cutaneous basal cell carcinoma: Evidence from an Italian case-control study. J Am Acad Dermatol2000;42:446–52.
62.
GreenAWilliamsGNealeR. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous-cell carcinomas of the skin: A randomised controlled trial. Lancet1999;354:723–9.
63.
KaragasMRStannardVAMottLA. Use of tanning devices and risk of basal cell and squamous cell skin cancers. J Natl Cancer Inst2002;94:224–6.
64.
ManICrombieIKDaweRS. The photocarcinogenic risk of narrowband UVB (TL-01) phototherapy early follow-up data. Br J Dermatol2005;152:755–7.
65.
HebertJLKhugyaniFAtharM. Chemoprevention of basal cell carcinomas in the ptc1+/– mouse—green and black tea. Skin Pharmacol Appl Skin Physiol2001;14:358–62.
66.
LichterMDKaragasMRMottLA. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol2000;136:1007–11.
67.
WagnerSLMalinerJSMortonWEBramanRS. Skin cancer and arsenical intoxication from well water. Arch Dermatol1979;115:1205–7.
68.
SassUTheunisANoelJC. Multiple HPV-positive basal cell carcinomas on the abdomen in a young pregnant woman. Dermatology2002;204:362–4.
69.
NoodlemanFRPollackSV. Trauma as a possible etiologic factor in basal cell carcinoma. J Dermatol Surg Oncol1986;12:841–6.
70.
Zak-PrelichMNarbuttJSysa-JedrzejowskaA. Environmental risk factors predisposing to the development of basal cell carcinoma. Dermatol Surg2004;30(2 Pt 2):248–52.
71.
KennedyCBajdikCDWillemzeRBouwes BavinckJN. Chemical exposures other than arsenic are probably not important risk factors for squamous cell carcinoma, basal cell carcinoma and malignant melanoma of the skin. Br J Dermatol2005;152:194–7.
72.
CzarneckiDTaitBNicholsonILewisA. Multiple non-melanoma skin cancer: Evidence that different MHC genes are associated with different cancers. Dermatology1994;188:88–90.
73.
WebbMCComptonFAndrewsPAKoffmanCG. Skin tumours posttransplantation: A retrospective analysis of 28 years' experience at a single centre. Transplant Proc1997;29:828–30.
74.
HarteveltMMBavinckJNKootteAM. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation1990;49:506–9.
75.
JensenPMollerBHansenS. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol2000;42(2 Pt 1): 307.
76.
LindelofBSigurgeirssonBGabelHSternRS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol2000;143:513–9.
77.
RobbinsJH. Xeroderma pigmentosum. Defective DNA repair causes skin cancer and neurodegeneration. JAMA1988;260:384–8.
78.
BodakNQueilleSAvrilMF. High levels of patched gene mutations in basal-cell carcinomas from patients with xeroderma pigmentosum. Proc Natl Acad Sci USA1999;96:5117–22.
79.
WeiQMatanoskiGMFarmerER. DNA repair capacity for ultraviolet light-induced damage is reduced in peripheral lymphocytes from patients with basal cell carcinoma. J Invest Dermatol1995;104:933–6.
80.
KraemerKHLeeMMAndrewsADLambertWC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol1994;130:1018–21.
81.
RamachandranSFryerAASmithAG. Basal cell carcinomas: Association of allelic variants with a high-risk subgroup of patients with the multiple presentation phenotype. Pharmacogenetics2001;11:247–54.
Guidelines of care for phototherapy and photochemotherapy.American Academy of Dermatology Committee on Guidelines of Care. J Am Acad Dermatol1994;31:643–8.
84.
ZhangHPingXLLeePK. Role of PTCH and p53 genes in early-onset basal cell carcinoma. Am J Pathol2001;158:381–5.
85.
RobinsonJK. Risk of developing another basal cell carcinoma. A 5-year prospective study. Cancer1987;60:118–20.
86.
MarghoobAKopfAWBartRS. Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. J Am Acad Dermatol1993;28:22–8.
87.
SchreiberMMMoonTEFoxSHDavidsonJ. The risk of developing subsequent nonmelanoma skin cancers. J Am Acad Dermatol1990;23(6 Pt 1):1114–8.
88.
VitasaBCTaylorHRStricklandPT. Association of nonmelanoma skin cancer and actinic keratosis with cumulative solar ultraviolet exposure in Maryland watermen. Cancer1990;65:2811–7.
89.
BoydASShyrYKingLEJr. Basal cell carcinoma in young women: An evaluation of the association of tanning bed use and smoking. J Am Acad Dermatol2002;46:706–9.
90.
MilanTVerkasaloPKKaprioJKoskenvuoM. Lifestyle differences in twin pairs discordant for basal cell carcinoma of the skin. Br J Dermatol2003;149:115–23.
91.
SmithJBRandleHW. Giant basal cell carcinoma and cigarette smoking. Cutis2001;67:73–6.
92.
ErbagciZErkilicS. Can smoking and/or occupational UV exposure have any role in the development of the morpheaform basal cell carcinoma? A critical role for peritumoral mast cells. Int J Dermatol2002;41:275–8.
93.
McNaughtonSAMarksGCGreenAC. Role of dietary factors in the development of basal cell cancer and squamous cell cancer of the skin. Cancer Epidemiol Biomarkers Prev2005;14:1596–607.
94.
VuralPCanbazMSekcukiDMuratA. Lipid profile in actinic keratosis and basal cell carcinoma. Int J Dermatol1999;38:439–42.
95.
BlackHSHerdJAGoldbergLH. Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med1994;330:1272–5.
96.
PerryPKSilverbergNB. Cutaneous malignancy in albinism. Cutis2001;67:427–30.
97.
GoeteynMGeertsMLKintADeWJ. The Bazex-Dupre-Christol syndrome. Arch Dermatol1994;130:337–42.
98.
HauckRMMandersEK. Familial syndromes with skin tumor markers. Ann Plast Surg1994;33:102–11.
99.
CribierBScrivenerYGrosshansE. Tumors arising in nevus sebaceus: A study of 596 cases. J Am Acad Dermatol2000;42(2 Pt 1):263–8.
100.
Hannuksela-SvahnAPukkalaEKarvonenJ. Basal cell skin carcinoma and other nonmelanoma skin cancers in Finland from 1956 through 1995. Arch Dermatol1999;135:781–6.
101.
HolmeSAMalinovszkyKRobertsDL. Changing trends in non-melanoma skin cancer in South Wales, 1988–98. Br J Dermatol2000;143:1224–9.
102.
GrayDTSumanVJSuWP. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol1997;133:735–40.
103.
HarrisRBGriffithKMoonTE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985–1996. J Am Acad Dermatol2001;45:528–36.
104.
GreenABattistuttaDHartV. Skin cancer in a subtropical Australian population: Incidence and lack of association with occupation. The Nambour Study Group. Am J Epidemiol1996;144:1034–40.
105.
BuettnerPGRaaschBA. Incidence rates of skin cancer in Townsville, Australia. Int J Cancer1998;78:587–93.
106.
HoyWE. Nonmelanoma skin carcinoma in Albuquerque, New Mexico: Experience of a major health care provider. Cancer1996;77:2489–95.
107.
GilesGGMarksRFoleyP. Incidence of non-melanocytic skin cancer treated in Australia. Br Med J (Clin Res Ed)1988;296:13–7.
108.
KrickerAArmstrongBKEnglishDRHeenanPJ. Pigmentary and cutaneous risk factors for non-melanocytic skin cancer—a case-control study. Int J Cancer1991;48:650–62.
109.
MarksRStaplesMGilesGG. Trends in non-melanocytic skin cancer treated in Australia: The second national survey. Int J Cancer1993;53:585–90.
110.
EnglishDRArmstrongBKKrickerA. Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: A case-control study. Int J Cancer1998;76:628–34.
111.
CookeKRSkeggDCFraserJ. Trends in malignant melanoma of skin in New Zealand. Int J Cancer1983;31:715–8.
112.
CookeKRFraserJ. Migration and death from malignant melanoma. Int J Cancer1985;36:175–8.
